Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dennis Yang

Gastroenterology Orlando, FL Medical Doctor

NPI 1013165182 CMS profile 45820

601 E Rollins St, Ste 5251, Orlando, FL 32803

Open in the dashboard

General payments

$349,031

414 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dennis Yang of Orlando, FL is reported in the CMS Open Payments database as having received $349,031 across 414 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $145,383 145
2024 General $113,363 125
2023 General $35,297 56
2022 General $52,558 75
2021 General $48 1
2020 General $364 4
2019 General $2,018 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dennis Yang
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Dennis Yang were reported at $145,383. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Dennis Yang Gastroenterology median Middle half National median
2019 $2,018 $417 $126–$1,100 $163
2020 $364 $224 $74–$624 $114
2021 $48 $352 $106–$1,054 $132
2022 $52,558 $448 $129–$1,270 $149
2023 $35,297 $533 $150–$1,390 $160
2024 $113,363 $605 $160–$1,606 $164
2025 $145,383 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Olympus Corporation of the Americas $210,177 264 payments
  2. Boston Scientific Corporation $40,639 49 payments
  3. Olympus America Inc. $37,453 27 payments
  4. Medtronic, Inc. $24,133 18 payments
  5. ERBE USA Inc $8,900 7 payments
  6. Micro-tech Endoscopy USA, Inc. $5,307 7 payments
  7. Neptune Medical Inc. $5,050 1 payment
  8. FUJIFILM Medical Systems USA, Inc. $4,727 8 payments
  9. Olympus Corporation $4,525 4 payments
  10. Olympus Medical Systems Corporation $2,878 2 payments
  11. Other $5,243 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $200,565 96 payments
  2. Consulting Fee $79,984 40 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $38,830 16 payments
  4. Travel and Lodging $19,199 136 payments
  5. Food and Beverage $8,953 125 payments
  6. Honoraria $1,500 1 payment
Products named General payments · program years 2019–2025
  1. Olympus EndoTherapy $170,707 104 payments
  2. Single Use Electrosurgical Knife KD-655 $170,090 205 payments
  3. DISPOSABLE DISTAL ATTACHMENT EndoTherapy $158,727 178 payments
  4. DISPOSABLE DISTAL ATTACHMENT EndoTherapy $49,868 67 payments
  5. Single Use Repositionable Clip $33,321 34 payments
  6. Olympus EndoTherapy $24,554 26 payments
  7. EVIS EXERA III COLONOVIDEOSCOPE $22,526 15 payments
  8. General - Therapies $21,361 10 payments
  9. Single Use Aspiration Needle NA-U200H $21,142 11 payments
  10. GASTROINTESTINAL VIDEOSCOPE $16,161 11 payments
  11. Other $93,608 217 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

111

Median for Gastroenterology: 569

Drug cost

$3,092

Median for Gastroenterology: $104,976

Branded share of claims

100%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 26 $1,710
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 65 $1,101
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 20 $281

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$88,579

Medicare's payments for the services billed

Medicare patients

241

Average age 74

Services billed

533

138 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 50%
Diabetes 44%
Chronic kidney disease 44%
Depression 31%
Atrial fibrillation 27%
Heart failure 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CREON
  • AbbVie, Inc. $40
$40 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

414 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record